Zai Lab
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Zai Lab concentrates its licensing activity in Oncology, InfectiousDisease. Zai Lab pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $160M. Most recent activity: 2023.
Pipeline coverage & gaps
Zai Lab has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 3 | $20M | $160M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2023 | Nuzyra (omadacycline) | Paratek Pharmaceuticals | Bacterial skin infections, pneumonia | approved | $15M | $150M |
| 2021 | Qinlock (ripretinib) | Deciphera Pharmaceuticals | Gastrointestinal Stromal Tumors (GIST) | approved | $20M | $192M |
| 2020 | lung_nsclc | Turning Point Therapeutics | lung_nsclc | phase_1 | $25M | $138M |
How this is computed
For each Zai Lab deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.194, clamped to [0.7, 1.5].